News | August 14, 2024
Marksans Pharma Q1 FY25 revenue up 18%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
US business grew by +12.8% YoY
Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Marksans' OTC Famotidine Tablets USP are acid reducers
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
Plans to double its manufacturing footprint to bolster the growth
Access Healthcare for Medical Products (Access Healthcare) provides pharmaceutical companies with innovative marketing and sales solutions in the MENA (Middle East & North Africa) region
The company has tied up with OrbiMed as a financial partner for global reach
Subscribe To Our Newsletter & Stay Updated
